Gapping up
In reaction to earnings/guidance:
- PERI +9.7%
Other news:
- NTLA +55.5% (Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis)
- AVXL +20.7% (reports ANAVEX2-73 (Blarcamesine) improved both primary cognitive and secondary MDS-UPDRS efficacy endpoints)
- ABUS +14.8% (New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress 2021 - All Selected for Best of ILC) MNKD +13.9% (policy change allows approval for Medicare patients living with diabetes to use both Afrezza And continuous glucose monitoring devices beginning July 18) DTIL +9.7% (Precision BioSciences and SpringWorks Therapeutics (SWTX) dose first patient in expanded phase 1/2a clinical trial evaluating PBCAR269A with nirogacestat in patients with relapsed/refractory multiple myeloma)
- SNDX +5.4% (receives Fast Track Designation from FDA for the treatment of relapsed/refractory acute leukemias)
- SANA +4.5% (Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates)
- RDHL +3.3% (announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva))
- MNOV +3.2% (to conduct mouse study under partnership with BARDA to develop MN-166 as a medical countermeasure against chlorine gas-induced lung injury)
- REGN +2.9% (Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis)
- CSIQ +1.7% (submits application documents for IPO for CSI Solar)
- VGZ +1.5% (receives final $1.0 million payment from Prime Mining Corp)
- HEXO +1.2% (announces closing of the previously disclosed transaction to purchase its first US production facility through a wholly owned US subsidiary)
- IMAX +1% (extending share-repurchase program through June 30, 2022)
Analyst comments:
- NKTR +3.2% (upgraded to Buy from Hold at Stifel)
- MAC +2.5% (upgraded to Buy from Hold at Deutsche Bank)
- NRG +2.4% (upgraded to Conviction Buy from Buy at Goldman)
- CX +2.1% (upgraded to Outperform from Neutral at Bradesco BBI)
- TOL +2% (upgraded to Neutral from Sell at BTIG Research)
- BEP +1.7% (upgraded to Outperform from Neutral at Credit Suisse)
- NCBS +1.7% (upgraded to Overweight from Equal-Weight at Stephens)
- IP +1.2% (upgraded to Overweight from Equal-Weight at Stephens)